A study to assess the combination of Famotidine and Celecoxib in patients COVID-19

Not Applicable

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

• Registration Number: CTRI/2022/09/045626
• Lead Sponsor: Sir Hurkisondas Nurrotumdas Reliance Foundation Hospital and Research Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients that are 18 years old and above who tested positive for COVID-19 using RT-PCR test <7 days ago.

2. WHO Clinical Progression Ordinal Scale scores between 1ââ?¬â??5

3. Informed consent signature.

Exclusion Criteria

1. WHO Clinical Progression Ordinal Scale scores of >5

2. Subjects with documented cardiac problem.

3. Subjects with diabetic nephropathy or chronic kidney disease ââ?¬â?? stage 3.

eGFR < 60mL/min

4. Known case of cancer.

5. Pregnant or nursing women.

6. Known allergy of COX2 inhibitor.

7. Subjects on Dexamethasone.

8. Belonging to another clinical trial that evaluates the efficacy of an investigational drug against COVID-19. The use of other treatments outside of clinical trials is allowed.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in C-reactive protein levels measured using blood test. <br/ ><br>Progression and resolution of complication and symptoms will be measured using the WHO Clinical Progression Scale. <br/ ><br>Viral load will be measured using Ct value from RT-PCR test. <br/ ><br>Timepoint: C-reactive protein - day 0,2,5,10,30 <br/ ><br>WHO Clinical Progression Scale- Day 0,1,2,3,5,10,30,60,90 <br/ ><br>RT-PCR test - Day 0, 3,5,10,30 <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
Resolutions of anosmia, cough, fever and other patient complaints. <br/ ><br>Changes in other inflammatory markers (Blood tests for Interleukin-6 (IL6), D-Dimer (DD), Lactate dehydrogenase enzyme (LDH) and Serum ferritin (SF)) <br/ ><br>Timepoint: Resolution of complaints - day 0,2,3,5,10,30,60,90 <br/ ><br>Other inflammatory markers - day 0,2,5,10,30